De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
Giuseppe Curigliano(European Institute of Oncology), Andrew Tutt(Institute of Cancer Research), José Baselga(Novartis (Switzerland)), Jacek Jassem(Gdańsk Medical University), Judy E. Garber(Dana-Farber Cancer Institute), Emiel J. Rutgers(Oncode Institute), Meredith M. Regan(Dana-Farber Cancer Institute), Jack Cuzick(Queen Mary University of London), Sara Y. Brucker(University Children's Hospital Tübingen), Fátima Cardoso(Breast Cancer Alliance), Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Prudence A. Francis(Peter MacCallum Cancer Centre), Nadia Harbeck(Breast Center), Chiun‐Sheng Huang(National Taiwan University Hospital), Carsten Denkert(Philipps University of Marburg), Bent Ejlertsen, Ian Smith(Queensland Health), Ann H. Partridge(Dana-Farber Cancer Institute), Lisa A. Carey(University of North Carolina at Chapel Hill), Marco Colleoni(European Institute of Oncology), Felix Sedlmayer, Roberto Orecchia(Istituti di Ricovero e Cura a Carattere Scientifico), Harold J. Burstein(Dana-Farber Cancer Institute), Hervé Bonnefoi, Bahadır M. Güllüoğlu(Marmara University), Kent C. Osborne(Baylor College of Medicine), Pamela J. Goodwin(Lunenfeld-Tanenbaum Research Institute), Beat Thürlimann(University of St.Gallen), Jens Huober(University of St.Gallen), Semiglazov Vf(Institute of Oncology NN Petrov), Daniel F. Hayes(University of Michigan–Ann Arbor), Eric P. Winer(University of Vermont), Olivia Pagani(Swiss Group For Clinical Cancer Research), Jonas Bergh(Karolinska Institutet), Zefei Jiang, Peter Dubsky(Hirslanden Klinik St. Anna), Eva Ciruelos(Hospital Universitario 12 De Octubre), Martine Piccart(Université Libre de Bruxelles), Sibylle Loibl(Goethe University Frankfurt), Per Karlsson(University of Gothenburg), Masakazu Toi(Mukogawa Women's University), Angelo Di Leo(Hospital of Prato), Hans-Jörg Senn(Breast Center), K. Pritchard(Sunnybrook Health Science Centre), Hussein Khaled(Cairo University), Monica Morrow(Memorial Sloan Kettering Cancer Center), Jungsil Ro(Western University), Fabrice André(Inserm), V.E. Galimberti(European Institute of Oncology), Zhi‐Ming Shao(Shanghai Medical College of Fudan University)
Cited by 1,253
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k